Payment overview · 2025
General Payments
$132.78
7 reported records · 5 companies
Healthcare provider profile · identity verified
Tedd L March, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · MONROE, MI · NPI 1043216658
Verified facts
What the public records show
CMS Open Payments records show Tedd L March, D.O. received $132.78 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.46 | 28.2% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $32.31 | 24.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.50 | 21.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.82 | 13.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.69 | 12.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $132.78 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $32.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 131 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
320 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
121 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 891 | 257 |
| Levothyroxine Sodium | Levothyroxine Sodium | 764 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 603 | 173 |
| Metformin Hcl | Metformin Hcl | 555 | 154 |
| Lisinopril | Lisinopril | 527 | 153 |
| Omeprazole | Omeprazole | 478 | 145 |
| Losartan Potassium | Losartan Potassium | 413 | 120 |
| Jardiance | Empagliflozin | 320 | 62 |
| Simvastatin | Simvastatin | 255 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 78 |
| Gabapentin | Gabapentin | 236 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 77 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 229 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 72 |
| Potassium Chloride | Potassium Chloride | 214 | 64 |
| Ipratropium Bromide | Ipratropium Bromide | 196 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 59 |
| Ozempic | Semaglutide | 174 | 35 |
| Chlorthalidone | Chlorthalidone | 171 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 164 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 48 |
| Carvedilol | Carvedilol | 150 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 59 |
| Allopurinol | Allopurinol | 143 | 39 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 143 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 52 |
| Meloxicam | Meloxicam | 138 | 41 |
| Sertraline Hcl | Sertraline Hcl | 137 | 35 |
| Furosemide | Furosemide | 136 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 134 | 31 |
| Trulicity | Dulaglutide | 132 | 31 |
| Eliquis | Apixaban | 131 | 43 |
| Trazodone Hcl | Trazodone Hcl | 122 | 33 |
| Mounjaro | Tirzepatide | 121 | 25 |
| Atenolol | Atenolol | 116 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 31 |
| Spironolactone | Spironolactone | 92 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 23 |
| Tramadol Hcl | Tramadol Hcl | 77 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 76 | 28 |
| Famotidine | Famotidine | 75 | 23 |
| Glimepiride | Glimepiride | 75 | 22 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 74 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 23 |
| Montelukast Sodium | Montelukast Sodium | 74 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 72 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 17 |
| Rybelsus | Semaglutide | 69 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 14 |
| Azelastine Hcl | Azelastine Hcl | 67 | 31 |
| Warfarin Sodium | Warfarin Sodium | 65 | 14 |
| Buspirone Hcl | Buspirone Hcl | 62 | 19 |
| Ibuprofen | Ibuprofen | 62 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 14 |
| Xarelto | Rivaroxaban | 55 | 14 |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Metformin Hcl Er | Metformin Hcl | 50 | 17 |
| Prednisone | Prednisone | 49 | 30 |
| Hydrocortisone | Hydrocortisone | 46 | 21 |
| Januvia | Sitagliptin Phosphate | 46 | 11 |
| Nifedipine Er | Nifedipine | 46 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 35 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 12 |
| Alprazolam | Alprazolam | 37 | 17 |
| Colchicine | Colchicine | 37 | 14 |
| Finasteride | Finasteride | 37 | 11 |
| Lorazepam | Lorazepam | 36 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 27 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 18 |
| Diazepam | Diazepam | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 22 |
| Celecoxib | Celecoxib | 31 | 11 |
| Etodolac | Etodolac | 31 | 13 |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 23 | 11 |
| Fluconazole | Fluconazole | 23 | 18 |
| Irbesartan | Irbesartan | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $132.78 · 7 records | Amgen Inc. | DUPIXENT, ELIQUIS, EVENITY, JOURNAVX, MOUNJARO, NURTEC ODT | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error